Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies

Sayed Shahabuddin Hoseini, Madelyn Espinosa-Cotton, Hong-fen Guo, Nai-Kong V Cheung

ABSTRACT

Background Leukemia represents about 5% of all human cancers. Despite advances in therapeutics, a substantial number of patients succumb to the disease. Several subtypes of leukemia are inherently more resistant to treatment despite intensive chemotherapy or targeted therapy.

Methods Here we describe the generation of T cell engaging (CD3) bispecific antibodies (BsAbs) built on humanized IgG frameworks using the IgG(L)-scFv format against two targets expressed on acute lymphoblastic leukemia (ALL) and on acute myeloid leukemia (AML).

Results Each BsAb mediated potent anti-leukemia effect against ALL (CD19) and AML (CD33) in vitro and in xenograft models. Importantly, the CD19-specific BsAb (BC250) was effective against hematogenous spread preventing metastases to liver and kidney in mice bearing ALL and Burkitt’s lymphoma xenografts. BC250 was more potent than the The Food and Drug Administration (FDA)-approved BsAb blinatumomab against ALL xenografts in vivo as measured by tumor bioluminescence and mouse survival. Furthermore, the combination of the CD19 and CD33 BsAbs in two xenograft models of mixed phenotype acute leukemia (biphenotypic and bilineal leukemia) was far superior than monotherapy with either of the BsAbs alone.

Conclusions Selective combinations of these leukaemia-specific BsAbs offer the potential to overcome tumor heterogeneity or clonal escape in the modern era of antibody-based T cell-driven immunotherapy.

INTRODUCTION

Leukemia is the most common cancer in children and its treatment in adults remains suboptimal. Although the advent of chimeric antigen receptor (CAR), bispecific antibodies (BsAbs) and targeted therapies has dramatically improved the outlook among these patients; survival remains poor among patients who relapse.1

Similar to solid cancers, both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are composed of heterogenous populations of cells that evolve during treatment where the composition of tumor cells could significantly differ before and after treatment or relapse, typically with dire therapeutic implications.2–5 In addition, mixed phenotype leukemia is composed of heterogenous populations of cells with different lineage phenotype including surface marker expression.6–8 With the advent of immunotherapy, leukemia clones could downregulate antigen expression, take advantage of splice variants, and even structural mutations.9–11 Antigen heterogeneity aside, leukemia could also exploit regulatory T cells that circulate in the blood of patients with AML, shown to be associated with poorer prognosis and resistance to therapy.12 13 Myeloid-derived suppressor cells constitute another family of cells in tumor microenvironment that can blunt immune surveillance; they have been shown to be expanded in patients with AML and to dampen the anti-leukemia immune response.14 15

Among the many resistance mechanisms, antigenic coverage seems the most logical next step. Myeloid leukemia switch is now recognized as an escape from CD19-chimeric antigen receptor T cell (CART) therapy.16 We propose to test the combination of T cell-based therapies directed at two lineage-specific antigens, using a tetravalent IgG(L)-scFv platform (anti-tumor IgG with anti-CD3 scFv fused to the light chains).17

In this manuscript, we generated BsAb built on humanized IgG frameworks directed at leukemia-associated antigens, CD19 and CD33. While monotherapy with each BsAb was potent in cytotoxicity assays and in xenograft models of leukemia, only the combination therapy was effective against mixed lineage leukemias.

METHODS

Generation of BsAbs

The murine FMC63 anti-CD19 antibody18 was humanized by grafting the heavy chain complementarity determining region (CDR) sequences onto the human framework IGHV4-4*08-IGHJ4*01, and the light chain CDR sequences onto the human framework IGLV1-65*01.
IGKV1-33*01-IGKJ2*01. The CDRs of the heavy and light chains of murine anti-CD33 My96 antibody were grafted onto human IgG1 frameworks based on their homology with human frameworks IGHV1-46*01-IJJ6*01 for VH, IGKV4-1*01-IGKJ4*01 for VL, respectively. All VH and VL domains have a combined average humanness of more than 85% (table 1).

The anti-CD19 BsAb (BC250) and anti-CD33 BsAb (BC269) were designed using VH/VL domains from the corresponding humanized antibodies and huOKT3 scFv fused to the C-terminus of the light chain of a human IgG1 based on a method described previously. To remove glycosylation and complement binding, the N297A and K322A mutations in the Fc region were made, respectively. Several anti-CD19 BsAb humanized variants with different affinities for CD19 were generated during a single humanization campaign and named as BC253, BC254, and BC255. BsAbs were expressed by transient transfection of Exp295F cells (ThermoFisher Scientific - Waltham, MA, USA) and purified using protein-A affinity columns using AKTA fast protein liquid chromatography (GE Healthcare - Chicago, IL, USA). Purity was assessed by high performance liquid chromatography. Blinatumomab was obtained from the Memorial Sloan Kettering Cancer Center (MSKCC) pharmacy.

Table 1 The humanness of anti-CD19 and CD33 antibodies

<table>
<thead>
<tr>
<th>Anti-CD19 agents</th>
<th>VH humanness</th>
<th>VL humanness</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD19 CAR (FMC63)</td>
<td>63.6</td>
<td>73.7</td>
</tr>
<tr>
<td>Glenmark hFMC63</td>
<td>81.8</td>
<td>88.4</td>
</tr>
<tr>
<td>BC250</td>
<td>84.5</td>
<td>86.3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Anti-CD33 agents</th>
<th>VH humanness</th>
<th>VL humanness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mylotarg</td>
<td>71.4</td>
<td>78</td>
</tr>
<tr>
<td>BC269</td>
<td>85.7</td>
<td>93</td>
</tr>
</tbody>
</table>

CAR, chimeric antigen receptor.

Cytotoxicity assay (chromium release assay)

Leukemia cells were cultured in RPMI1640 (Corning Scientific - Corning, NY, USA) supplemented with 10% fetal bovine serum (Life Technologies - Carlsbad, CA, USA) at 37°C in a 5% CO2 humidified incubator. Cytotoxicity assay was performed as described before.

Cell lines and fluorescence activated cell sorting (FACS) analysis

NALM6-luciferase cells were provided by Renier J. Brentjens at MSKCC. CD19-negative NALM6-luciferase cells...
were provided by David Scheinberg (MSKCC). These cells were transduced with human CD33 gene whose construct was provided by Trinidad Hernández-Caselles (IMIB-University of Murcia).24

BV173-luciferase cells were provided by R.J. O’Reilly (MSKCC). Raji and Daudi cells were transduced with retroviral virus to express click beetle luciferase (kindly provided by Vladimir Ponomarev (MSKCC)). JIH-5 cells were bought from DSMZ (Leibniz, Germany). MOLM13-luciferase cells were provided by David Scheinberg (MSKCC).

Anti-human antibodies against CD3, CD4, CD8, CD19, and CD33 (Biolegend - San Diego, CA, USA) were used to stain cells. Stained cells were processed with a FACScalibur instrument (BD Biosciences - San Jose, CA, USA) and analyzed with FlowJo software (FlowJo, Ashland, Oregon, USA).

**In vivo studies**

All mouse experiments were performed in compliance with the Institutional Animal Care and Use Committee guidelines. The immunodeficient NOD.Cg-Prkdcsid IL-2Rγc/−/− /Sj (NSG) mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA) and provided with Sulfatrim food. For tumor challenge experiments, 6–10-week-old mice were inoculated with leukemic cells intravenously with (0.5–1×10⁶ cells). For intravenous-leukemia model, activated human T cells (ATC) that were in culture for 7–9 days were admixed with the BsAb and were intravenously injected weekly for 1–3 weeks starting 3–6 days after tumor inoculation. BC119 (CD3xGD2 BsAb) was used as a control since GD2 is not expressed by any of the leukemia cell lines used. One thousand international unit of interleukin 2 (IL-2) was subcutaneously injected two times per week to support T cell persistence. Tumor growth was monitored using the IVIS bioluminescence imager.

**Pharmacokinetics assessment**

Five 12-week-old female C57BL/6 mice were injected retroorbitally with 100 µg BC250. Blood was collected at 4, 8, 24, 48, 72, and 96 hours after BC250 administration. Immediately after collection blood was centrifuged at 800g for 10 min to separate serum and serum was frozen at −80°C. Serum antibody concentration was measured using ELISA. Briefly, huCD3 was adsorbed onto 96-well microtiter plates to capture the serum and BC250 were detected with peroxidase-conjugated mouse anti-human IgG1 (Jackson ImmunoResearch - West Grove, PA, USA) using o-phenylenediamine dihydrochloride as substrate.

**Statistical analysis**

Statistical analyses were performed using Graphpad Prism software. Comparison between two groups were performed using a Student’s t-test and comparisons between multiple groups were determined by analysis of variance (ANOVA) with Tukey correction and multiple

![Figure 2](http://jitc.bmj.com/firstpublishedas/10.1136/jitc-2020-001626.on25.November.2020.Downloadedfromhttp://jitc.bmj.com/onJanuary29,2021byguest.Protectedbycopyright.)

**Figure 2** A low dose of the CD19-specific BsAb redirects polyclonal T cells to treat ALL xenografts in vivo. (A–C) Immunodeficient NSG mice were intravenously inoculated with CD19(+) NALM6-luciferase human ALL xenografts (0.5×10⁶ cells). Therapy was started after 3 days. Mice received weekly injections of 10⁷ ATC with different doses of BC250. In the control groups, mice either received ATCs or a control GD2 BsAb with ATCs. Leukemia growth was monitored using the IVIS bioluminescent imager (A–B) and survival was assessed over time. Area under the curve of the log total flux until day 17 was compared between groups using ANOVA and multiple comparison analysis (C). All mice received subcutaneous injections of interleukin-2 (1000 IU/2 times/week). The experiment with NALM6 cells was repeated two times. ALL, acute lymphoblastic leukemia; ATC, activated human T cells; BsAb, bispecific antibody; ANOVA, analysis of variance.
RESULTS
CD19-BsAb-mediated antibody-dependent T cell-mediated cytotoxicity (ADTC) against ALL cell line at femtomolar EC50 in vitro
BsAb engaging T cells toward CD19 on ALL were made using the IgG(L)-scFv platform (figure 1A). The human-ness of published humanized CD19 antibodies is summarized in table 1. These BsAb bound to CD19(+) ALL cells, carrying out ADTC at femtomolar EC50 concentrations (figure 1B,C). Antibody binding avidity, measured by flow cytometry correlated with ADTC potency (EC50) in cytotoxicity assays (figure 1D,E). Clone BC250 demonstrated the highest binding and potency against CD19(+) leukemia and was chosen for further testing (figure 1D).

BsAb targeting CD19 and polyclonal T cells could ablate ALL xenografts in vivo
To test the in vivo potency of BC250, NSG mice were inoculated intravenously with CD19(+) NALM6 ALL cells. After 3 days, treatment was started with weekly intravenous injections of 10 million human ATC co-administered with decreasing doses of BC250 two times per week. One hundred nanogram of BC250 in the presence of ATC was curative while 100 ng of control BsAb specific for GD2 (which is not expressed on NALM6) or ATC alone had no effect. Survival of the BC250-treated mice was also significantly improved (figure 2).

To evaluate the potency of BC250 across various CD19(+) lymphoid malignancies, NSG mice were inoculated intravenously with B-cell lymphoma cell lines Daudi or Raji, or the B cell precursor leukemia cell line BV173. Treatment was started after 3 days (Raji) or 14 days (Daudi and BV173). While the combination of human ATC with BC250 treated leukemic mice, control GD2 BsAb was completely ineffectual similar to the no treatment group (figure 3 and online supplemental figure 1). The dose of T cells required for leukemia control varied with tumor model depending on the doubling time of xenografts. For BV173 cells, a single dose of 9 million T cells followed by six doses of BC250 was enough to cure leukemia, while three doses of T cells and BC250 were needed to control Daudi and Raji cells in mice. Furthermore, flow cytometry assessment of kidney and liver showed CD19(+) leukemia/lymphoma (Daudi and BV173) in untreated and in control BsAb/ATC-treated mice; in contrast, no tumor cells were detected in the BC250/ATC groups (figure 3B,D).

Figure 3  The combination of BC250 and T cells treats mice in several ALL xenograft mouse models in vivo. (A–E) Immunodeficient NSG mice were intravenously inoculated with CD19(+) Daudi-luciferase (10^6), BV173-luciferase (10^6), or Raji-luciferase (0.5×10^6). Treatment was started after 3 ((E), Raji) or 14 ((A) and (C), Daudi and BV173) days of leukemia engraftment. Treatment consisted of ATC injections (three doses each 20×10^6 for Daudi, one dose of 8.8×10^6 for BV173, or three doses each 10×10^6 for Raji) with BC250 (CD3xCD19 BsAb) or a GD2 BsAb control antibody. Interleukin two was administered two times per week (1000 IU) to support ATC persistence. Leukemia growth was monitored using the IVIS bioluminescent imager. 39 days after leukemia injection, mice were sacrificed and kidney (Daudi group) or liver (BV173) were analyzed by flow cytometry for the presence of leukemic cells (B and D). The experiment with Raji cells was repeated two times. Area under the curve of the log total flux was compared between groups using ANOVA and multiple comparison analysis. ALL, acute lymphoblastic leukemia; ATC, activated human T cells; BsAb, bispecific antibody; ANOVA, analysis of variance.
Open access

BC250 was superior to blinatumomab against ALL xenografts in vivo

Blinatumomab (Blincyto) is a tandem scFv bispecific T cell engager (BiTE) against CD19 and the only Food and Drug Administration (FDA)-approved BsAb against ALL and lymphoma (figure 4A). The potency of BC250 and blinatumomab were compared in ADTC (figure 4B). In vitro, BC250 and blinatumomab appear to have very similar potencies (EC50, 0.65 vs 3 pM), although blinatumomab demonstrated slightly higher maximum killing at the higher antibody concentrations (figure 4B). To compare the potency of the drugs in vivo, NSG mice inoculated with NALM6 human ALL cells were treated with BsAbs in combination with ATC. To compensate for the monovalent CD19/CD3 binding of blinatumomab versus bivalent binding of BC250 to CD19/CD3, a twofold higher molar dose of blinatumomab was administered. In addition, to compensate for the short in vivo half-life of blinatumomab, both antibodies were injected daily. As shown in figure 4C, D, as low as 5 fmol of BC250 could reduce leukemia growth and improve mice survival while 10 fmol of blinatumomab did not have any benefit over the T cell-only control group (figure 4D top panels, p=0.0001 and p=0.006 for tumor signal at days 10 and 17; p=0.0034 for survival). For the second dose group (50–100 fmol), there was a significant benefit of BC250 over blinatumomab for both leukemia burden and survival (figure 4D middle panel, p=0.001 for tumor signal at days 10 and 17; p=0.0027 for survival). Higher doses of both BsAbs could significantly reduce the leukemia growth, however, BC250 seemed superior in reducing the leukemia growth and survival extension (figure 4D lower panel, p=0.01 for tumor signal at day 10; p=0.062 for survival).

Superior potency of BC250 over blinatumomab is more than its favorable PK

Blinatumomab is a 54 KD protein whose molecular weight is below the kidney clearance (70 kD) and therefore it has a poor PK with an elimination half-life (T1/2) of 2.1 hours (blinatumomab FDA label). To assess the mechanism of BC250’s superior in vivo potency, we assessed the PK of BC250 in mice (figure 5A). The T1/2 of BC250 in this experiment was ~19 hours, approximately nine times the T1/2 of blinatumomab. BC250 remained detectable in two of five mice for up to 96 hours post injection. To investigate other potential mechanisms of BC250’s superior potency, we conducted an in vivo armed-T cell study. Activated T cells were mixed with either BC250 or blinatumomab
Open access

for 20 min in a small volume of media (50 µL) and the unbound antibody was washed away. Equimolar doses of BC250 and blinatumomab were chosen, corrected for the bivalency of BC250 versus the univalent structure of blinatumomab, meaning that two times as many moles of blinatumomab were used compared with BC250 to arm the T cells. Armed-T cells were injected into mice that had been inoculated with NALM6 leukemia 10 days prior. BC250 armed-T cells reduced tumor burden 4.7-fold and 3.8-fold by days 21 (p=0.03) and 25 (p=0.017), respectively, and extended the survival of the leukemic mice (7/10 BC250 mice alive on day 47 versus 0/10 blinatumomab mice, p<0.0001) (figure 5D). These data demonstrate that the superiority of BC250 over blinatumomab cannot be entirely attributed to its more favorable PK and suggest that bivalent binding of BC250 versus monovalent binding of blinatumomab plays an important role in vivo.

Combining BsAb specific for CD19 and CD33 for biphenotypic leukemia

Mixed-phenotype acute leukemia (MPAL) is a heterogeneous type of acute leukemia with the expression of myeloid and lymphoid markers on a single type of blast cells (biphenotypic acute leukemia, BAL) or a discrete admixed population of myeloid and lymphoid blasts (bilineal leukemia). B/myeloid leukemia is the most common type of MPAL. JIH-5 is a human B lymphoid BAL cell line with homogenous expression of CD19 on all cells and variable expression of CD33 on subpopulations (figure 6A). We previously reported a humanized T cell-engaging BsAb against CD33 (BC133) based on the CD3 clone M195 with potent anti-AML function in vitro and in vivo. However, the CD3xCD33 BsAb we reported in this manuscript (BC269) has 24-fold higher affinity to CD33 and improved cytotoxicity in ADTC assays (fivefold lower EC50, figure 6B) and a better humanness score (humanness score of 93% vs 76.6% for VL and 85.7% vs 76.5% for VH for BC269 vs BC133, respectively) (table 2). To test the effect of combined BsAb therapy, the susceptibility of this cell line to monotherapy or combination therapy with anti-CD19 (BC250) and anti-CD33 (BC269) BsAbs was assessed in ADTC. The maximum killing of BC269 was about 50% of the maximum killing of BC269/BC250 combination therapy, consistent with the partial expression of CD33 on BAL cells (figure 6C). Since CD19 was expressed on all JIH-5 cells, BC250 monotherapy was as effective as BC250/BC269 combination therapy. To test the combination therapy of BsAbs against BAL, NSG mice were inoculated with a mixture of CD19(−)CD33(+) and CD19(+)CD33(−) NALM6 cells. Whereas treatment with either BC250 or BC269 in the presence of ATC did...
not prevent tumor growth, combination therapy of the same two BsAbs showed strong anti-leukemia responses (figure 6D,E).

Combining CD19-BsAb and CD33-BsAb in T cell therapy of bilineal leukemia

Another type of MPAL is acute bilineal leukemia where discrete admixed populations of myeloid and lymphoid blasts coexist in the same patient. In ADTC assays where target cells were composed of a mixture of CD19(+) NALM6 and CD33(+) MOLM13 cells, the combination of BC250 and BC269 showed an additive effect at higher antibody concentrations (figure 7A). In a xenograft model of bilineal leukemia generated by intravenous injection of equal numbers of CD19(+) ALL and CD33(+) AML cells, the combination of CD19-BsAb and CD33-BsAb suppressed tumor growth, in contrast to groups treated with either BC250 or BC269 alone (figure 7B,C).

**DISCUSSION**

Most adults with ALL relapse after achieving a complete remission and the majority of patients succumb to leukemia, however, about 25% never achieve a complete remission at all.26 For AML, the prognosis is even worse. In this manuscript, we reported the generation of two humanized T cell engaging BsAbs against CD19 and CD33 using a tetravalent IgG(L)-scFv platform (anti-tumor IgG with anti-CD3 scFv fused to the light chains), one of the most potent BsAb platforms. Placing tumor and T-cell binding domains on the same side of a BsAb (cis

<table>
<thead>
<tr>
<th>VH humanness%</th>
<th>VL humanness%</th>
<th>ka (1/Ms)</th>
<th>kd (1/s)</th>
<th>KD (M)</th>
<th>EC50 (μg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BC269</td>
<td>85.7</td>
<td>93</td>
<td>7.84E+05</td>
<td>6.58E-04</td>
<td>1.02E-10</td>
</tr>
<tr>
<td>BC133</td>
<td>76.6</td>
<td></td>
<td>9.85E+05</td>
<td>7.97E-03</td>
<td>2.47E-09</td>
</tr>
</tbody>
</table>

BsAb, bispecific antibody.
configuration) elicits substantially stronger anti-tumor activity, in vitro and in vivo, compared with positioning them on opposite sides (trans configuration). Moreover, using two cis-modules in the same BsAb further improved cytotoxicity (up to 2000-fold). Additionally, separating antigen-binding components with a single Ig domain (CL) dramatically enhanced cytokine release and in vivo tumor responses compared with smaller (G4S1) or larger (CH1–CH2–CH3) spacers.

In this manuscript we show that whereas each antibody alone was able to retarget polyclonal T cells to treat antigen(+) target cells, the combination of these antibodies was successful in treating various forms of MPAL (bilineal and biphenotypic leukemia) in animal models. In the case of CD19-BsAb (BC250), a comparison was made against blinatumomab, the only FDA-approved BsAb to treat leukemia/lymphoma. BC250 was more potent than blinatumomab in reducing tumor burden and increasing survival of leukemic mice using a daily injection regimen to compensate for the fast pharmacokinetics of blinatumomab (2 hour serum half-life).27 Using T cells armed ex vivo with BsAb (thereby excluding the confounding effect of poor PK of blinatumomab), we proved the definitive advantage of BC250 over blinatumomab in vivo. Since in these T cell-arming experiments any unbound BsAb was removed, T cell surface-bound BC250 was able to outperform surface-bound blinatumomab, a property we have previously described,17 and has since been validated in a number of BsAbs targeting CD33, GD2, Her2, and GPA33 using this unique IgG-L-scFv format.21 23 28 29 In addition to its superior potency, unlike blinatumomab, our anti-CD19 VH had 84.5% humanness while VL had 86.3% humanness, vs 69.4% and 65.3% for the humanness of blinatumomab’s VH and VL, respectively), which translates into a reduction in immunogenicity and neutralizing antibody generation, potential hurdles for retreatment with blinatumomab or current mouse scFv-based CD19 CART. To assess the effect of antibody affinity on its potency, we tested four different humanized versions of the CD19 BsAb in T cell dependent cytotoxicity assays. Importantly, there was a correlation between antibody affinity and potency, where BC250 with the highest affinity (lowest kD) was the most potent (lowest EC50). The effect of affinity on potency has previously been reported for the BiTE format.30 However, there was also a ceiling beyond which further affinity maturation did not improve ADTC in vitro or in vivo.26 Our results confirmed the affinity range (100 nM to 0.1 nM) where improvements can be expected.31–33

The FDA approval of CD19 CART cells paved the way to improve survival rates of patients with ALL. Despite efforts to increase the accessibility of CART therapies...
by generation of off-the-shelf allogeneic CART cells, the current FDA-approved CD19 CART products are primarily derived from autologous sources, where the associated manufacturing complexity prevents this therapeutic modality to be used as an off-the-shelf treatment. The processing time required for cell manufacturing can make CART cells unsuitable for at least 30% of patients. Furthermore, unintentional transduction of leukemic cells with the CAR gene during manufacturing has been associated with CD19 recognition blockade leading to leukemia relapse. In addition, the long-term persistence of CART cells may prevent normal hematopoiesis following the induction of remission and in the case of CD19 leading to prolonged B-cell cytopenia and hypogammaglobulinemia. Furthermore, CARTs against myeloid leukemia have yet to be FDA approved. Mono-specific CARTs could not prevent relapse related to lineage switch, epitope loss or splice variants, and they cannot be used to treat patients with MPAL.

Other mechanisms of leukemia escape after CART or BsAb treatment have recently emerged. One such mechanism, lineage switch, has been reported in patients with B-ALL developing mixed lineage leukemia harboring the MLL gene after CD19 CART or T cell-engaging BsAb blinatumomab therapies. In addition, leukemia relapse secondary to the selection for pre-existing CD19 spliced variants lacking the CD19 epitope or CD19 loss could be found in up to 20% of patients treated with CD19 CART cells or blinatumomab. Furthermore, those leukemias carrying different markers on distinct lineages are not expected to be curable with a single antibody alone. The use of dual-specific CART cells that express two different scFvs specific for two separate leukemia antigens might be an alternative; however, it may not easily permit balanced or controlled expression of one scFv over the other. Here, the fine tuning of the two specificities as the leukemia lineages contract or expand could be difficult to orchestrate. Mixing two or more CART cell populations could be another alternative; however, this will add more complexity to an already demanding manufacturing process. With dual-specific CARs toxicity could mount and inclusion of separate suicide genes for each CART product can further complicate their clinical development. In addition, these suicide genes are not available in the current FDA-approved CART cell products or been adequately tested in large enough sample size. On the other hand, combination antibody therapy is now acceptable in immuno-oncology, although combination BsAb strategies will need more careful consideration. It is conceivable that the dose of each antibody can be adjusted for each indication, while each can be individually interrupted or stopped, to reduce side effects or on disappearance of the cell population targeted by the antibody (eg, in case of MPAL). BsAbs with potency for two different tumor associated antigens have been generated; however, selection of clones with dual specificity for both antigens and the potential of cross reactivity to other antigens complicates generation of such antibodies. Besides, the dose of antibody for each target could not be adjusted separately. The combination of BsAbs to target various antigens on tumor cells could reduce the chance of relapse. For example, combining CD19 and CD22 BsAbs could reduce the chance of CD19(−) relapse of patients with B-cell malignancies.

One of the important complications of CD19 CART and blinatumomab therapy is the development of neurotoxicity. We did not observe any neurological adverse effects in mice treated with BC250 or blinatumomab. One of the suggested mechanisms of neurotoxicity is the expression of CD19 on brain pericytes; however, the lack of cross-reactivity of these antibodies to mouse CD19 did not allow us to assess this phenomenon in our experiments. Nevertheless, we do not expect BC250 format to cross the blood brain barrier due to its larger size as we have not observed toxicity with other BsAb built on the same format even when the target is on mouse brain (unpublished results from GD2xCD3 BsAb). Hence, a limitation of our BsAb is that it may not treat central nervous system (CNS) leukemia, unlike blinatumomab or CD19 CART cells.

To conclude, we demonstrated that by combining powerful anti-leukemia BsAbs based on the IgG(L)-scFv platform for common lymphoid and myeloid markers (CD19 and CD33) the T cell-based treatment of ALL, AML, and MPAL could be improved.
REFERENCES